Information Provided By:
Fly News Breaks for December 15, 2017
BSX, CSII
Dec 15, 2017 | 07:54 EDT
As reported earlier, Needham analyst Mike Matson downgraded Cardiovascular Systems (CSII) to Hold from Buy. Matson says he sees limited upside potential for FY18 consensus revenue and also notes a potential competitive threat from Boston Scientific's (BSX) new version of Rotablator expected in early 2018. The analyst contends that Cardiovascular Systems shares are fairly valued based on his revenue growth forecasts.
News For CSII;BSX From the Last 2 Days
BSX
Mar 26, 2024 | 05:33 EDT
Scivita Medical and Boston Scientific joined hands again to sign an expanded strategic cooperation arrangement. The introduction of iterative endoscopic technology has brought about a positive transformation in the field of endoscopy, making it an interventional tool that combines diagnosis and treatment. Under the arrangement, Scivita Medical will expand its relationship with Boston Scientific for strategic co-development and global distribution activities. Such activities may include collaboration on the co-development of future endoscopic devices, and global distribution opportunities for Scivita Medical's single-use endoscope and imaging devices. It is expected that this expanded arrangement will help bring Scivita Medical products to more hospitals and patients throughout China and other global geographies.